DNTH
NASDAQDianthus Therapeutics Inc.
News25/Ratings12
News · 26 weeks56-70%
2025-10-262026-04-19
Mix4190d
- SEC Filings14(34%)
- Insider13(32%)
- Other6(15%)
- Earnings3(7%)
- Offering3(7%)
- Analyst2(5%)
Latest news
25 items- INSIDERSEC Form 4 filed by Savitz Ryan4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- SECSEC Form DEFA14A filed by Dianthus Therapeutics Inc.DEFA14A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
- SECSEC Form DEF 14A filed by Dianthus Therapeutics Inc.DEF 14A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
- ANALYSTWolfe Research initiated coverage on Dianthus Therapeutics with a new price targetWolfe Research initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $98.00
- PRDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW YORK and WALTHAM, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on April 1, 2026, to eight newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants consist of non-qualified stock options to purchase an aggregate of 135,000 shares of the Co
- INSIDERSEC Form 4 filed by Savitz Ryan4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- INSIDERSEC Form 4 filed by Soteropoulos Paula4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- INSIDERSEC Form 4 filed by Soteropoulos Paula4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- SECDianthus Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
- INSIDERCEO AND PRESIDENT Garcia Marino exercised 65,292 shares at a strike of $7.66 (SEC Form 4)4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- INSIDERCHIEF ACCOUNTING OFFICER Carr Edward exercised 43,682 shares at a strike of $20.45 and sold $3,559,495 worth of shares (43,682 units at $81.49) (SEC Form 4)4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- INSIDEREVP, Head of R&D Randhawa Simrat exercised 33,830 shares at a strike of $18.15 and sold $2,756,468 worth of shares (33,830 units at $81.48) (SEC Form 4)4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- INSIDERCEO AND PRESIDENT Garcia Marino exercised 122,918 shares at a strike of $6.70 and sold $10,016,381 worth of shares (122,918 units at $81.49) (SEC Form 4)4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- SECSEC Form 144 filed by Dianthus Therapeutics Inc.144 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
- SECSEC Form 144 filed by Dianthus Therapeutics Inc.144 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
- PRDianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesNEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH) ("Dianthus" or the "Company"), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it closed its previously announced underwritten public offering of 8,470,989 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 1,157,407 shares, at a public offering price of $81.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 402,468 shares of its common stock at a pub
- SECSEC Form 8-K filed by Dianthus Therapeutics Inc.8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
- SECSEC Form 424B5 filed by Dianthus Therapeutics Inc.424B5 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
- PRDianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public OfferingNEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH) ("Dianthus" or the "Company"), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the pricing of its previously announced upsized underwritten public offering of 7,313,582 shares of its common stock at a public offering price per share of $81.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 402,468 shares of its common stock at a public offering price of $80.999 per pre-funded warrant. The pre-funded warrants have an exercise price o
- SECSEC Form S-3MEF filed by Dianthus Therapeutics Inc.S-3MEF - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
- ANALYSTDianthus Therapeutics upgraded by Raymond James with a new price targetRaymond James upgraded Dianthus Therapeutics from Outperform to Strong Buy and set a new price target of $123.00
- SECSEC Form 424B5 filed by Dianthus Therapeutics Inc.424B5 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
- PRDianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public OfferingNEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH) ("Dianthus" or the "Company"), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it has commenced an underwritten public offering of $400 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Dianthus expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock at the public offering price, l
- SECSEC Form S-8 filed by Dianthus Therapeutics Inc.S-8 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
- SECSEC Form 10-K filed by Dianthus Therapeutics Inc.10-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)